Vibeke Strand, MD
Vibeke Strand, MD
Clinical Professor, Adjunct
Division of Immunology/Rheumatology,
Stanford University School of Medicine
Office: 306 Ramona Road
Portola Valley CA 94028
Dr. Strand serves a consultant in clinical research and regulatory affairs to pharmaceutical and biotech companies. She graduated from Swarthmore College with honors, attended the University of California, San Francisco School of Medicine and returned there to complete her subspecialty Rheumatology Fellowship. She was one of eight in the first Primary Care Internal Medicine Residency at Michigan State University. She has been a clinical rheumatologist for 30 years - in subspecialty practice in San Francisco, as a clinical investigator, as an IRB member and subsequently as the director of clinical research at 3 pharmaceutical and biotech companies. She is a member of the clinical faculty at Stanford University, serving as Clinical Professor, Adjunct, Division of Immunology and Rheumatology since September 2000; Clinical Associate Professor since March 1993, and previously as Assistant and Associate Clinical Professor at University of California San Francisco (1981-1993). Her professional interests include development of outcome measures methodology, and clinical and regulatory strategies leading to approval of new agents for treatment of autoimmune diseases, including rheumatoid arthritis [RA], osteoarthritis [OA], fibromyalgia [FMS], gout, systemic lupus erythematosus [SLE] and systemic sclerosis [SSc].
Since 1991, Dr. Strand has led a consulting practice offering clinical research and regulatory expertise. Her focus is to help translate basic research into rational design of randomized controlled trials, evaluate their results and defend approval of novel products to FDA and EMA. She has assisted in preparation of applications, briefing documents and data presentation for defense of NDA and BLA applications, in HIV, BMTx, CTCL, uveitis, RA, OA, FMS, gout and SLE. She has been an invited speaker at FDA Arthritis Advisory Committee meetings discussing Guidance Documents for RA, OA, SLE, JRA, radiographic analyses in RA and outcome measures in pain, FMS and gout.
Her commitment to promoting forums for the discussion of rational product development among industry, FDA and academia led to her establishing and co-chairing the biyearly “Innovative Therapies in Autoimmune Disease” meetings (1988–2007), serving as a member of the executive organizing committee of the international Outcomes in Rheumatology Clinical Trials (OMERACT 1–11) consensus conferences (1992–2012), co-chairing OMERACT 7 (2004) and upcoming 11 (2012) meetings. She helped found and co-chaired the Clinical Immunology Society Spring Fellows School (2004–2008). Since 2005 she has served as a member of the Board of Directors of the Northern California Chapter of the Arthritis Foundation and their Medical and Scientific Committee, the Board of Directors of the Consortium of Rheumatology Researchers of North America: CORRONA (2002-2008) and currently, the Scientific Advisory Board of CORRONA (2010–).
She has authored over 230 original publications and reviews, 50 chapters, co-edited several books and multiple proceedings. She is a Fellow of the American College of Physicians (1982), a Fellow of the American College of Rheumatology (1986), serves on the editorial board of multiple journals, and is a member of the Cosmos Club (1994).
Strand V, Kimberly R, Isaacs JD: Biologic therapies in rheumatology: lessons learned, future directions. Nature Reviews Drug Discovery 2007; 6:75-92. PMID: 17195034
Strand V. In Patients with Cardiovascular Risk Receiving Low Dose Aspirin, is a COX-2 Selective Agent Preferable to nsNSAIDs for Antiinflammatory Therapy? Lancet 2007; 370: 2138-51. PMID: 18156036
Strand V, Sokolove J: Randomized Controlled Trial Design in Rheumatoid Arthritis – The Past Decade. Arth Research Therapy 2009; 11:205-15. PMID: 19232061
Strand V, Crawford B, Singh J, Choy E, Smolen JS, Khanna D: Viewpoint: Use of “Spydergrams” to present and interpret Health related quality of life data across rheumatic diseases. Ann Rheum Dis 2009; 68:1800-04. PMID: 19910301
Strand V, Bloch D, Leff R, Peloso P, Simon LS: Safety Issues in the Development of Treatments for Osteoarthritis: Recommendations of the Safety Considerations Working Group. Osteo Arth Cart 2011: in press.
Strand V and Chu A: Measuring Outcomes in SLE Clinical Trials. Expert Review Pharmacoeconomics & Outcomes Research 2011: in press.